FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 0R 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) July 30, 2003

BIOCRYST PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)

DELAWARE
(State or Other Jurisdiction of Incorporation or Organization)

000-23186
(Commission File Number)

62-1413174
(I.R.S. Employer Identification No.)

2190 Parkway Lake Drive; Birmingham, Alabama 35244
(Address and Zip Code of Principal Executive Offices)

(205) 444-4600
(Registrant’s Telephone Number, Including Area Code)

NONE
(Former Name or Former Address, if Changed Since Last Report)

Item 7. Financial Statements and Exhibits

The exhibit listed below is being furnished pursuant to Item 12 of Form 8-K.

	Number		Description
	99.1		Press release dated July 30, 2003 entitled “BIOCRYST REPORTS SECOND QUARTER 2003 FINANCIAL RESULTS”.

Item 12. Results of Operations and Financial Condition:

12.1

On July 30, 2003, BioCryst Pharmaceuticals, Inc. issued a news release announcing its financial results for the quarter ended June 30, 2003. A copy of the news release is attached as an exhibit hereto and incorporated by reference into Item 12 of Form 8-K.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: July 30, 2003

BIOCRYST PHARMACEUTICALS, INC.

/s/ Michael A. Darwin
——————————————
Michael A. Darwin
Chief Financial Officer and
Chief Accounting Officer

INDEX TO EXHIBITS

	Exhibit Number		Description		Sequentially Numbered Page
	99.1		Press release dated July 30, 2003 entitled “BIOCRYST REPORTS SECOND QUARTER 2003 FINANCIAL RESULTS”.		3